January 11, 2019
ITN073ST, Immune Tolerance Network's (ITN's) LITTMUS clincial trial is now open with site activation as of today at Massachusetts General Hospital (MGH). Trial development has been a multi-year effort, with the ITN kick-off initiated at the American Transplant Congress in May 2016. Since that time Lamia Sun has been the consistent operations leader of both the protocol team and the companion ITN074ST UCSF LITTMUS Study protocol team. The studies will expand our portfolio of interventional tolerance studies in liver transplantation with state of the art Treg-based post-transplant therapies. Lamia has consistently kept the large and diverse protocol writing teams moving forward and today we are fortunate to enter the next stage of enrollment of the MGH trial. Congratulations to Lamia and the team on this terrific accomplishment!
More Information
